The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin - The Sit2Mix trial

Primary Care Diabetes

Volumn 9, Issue 5, 2015, Pages 370-376

  Linjawi, Sultan ^a   Sothiratnam, Radhakrishna ^b   Sari, Ramazan ^c   Andersen, Henning ^d   Hiort, Line Conradsen ^d   Rao, Paturi ^e  

^a Coffs Endocrine and Diabetes Services ^*  (Australia)

^b Columbia Asia Hospital ^*  (Malaysia)

^c AKDENIZ UNIVERSITY   (Turkey)

^d NOVO NORDISK A S   (Denmark)

^e NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Biphasic insulin; Randomized trial; Sitagliptin; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; METFORMIN; SITAGLIPTIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; BIPHASIC INSULIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN ASPART, INSULIN ASPART PROTAMINE DRUG COMBINATION 30:70; ISOPHANE INSULIN;

ADD ON THERAPY; ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WEIGHT CHANGE; AGED; ASIA; AUSTRALIA; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; ECONOMICS; EUROPE; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; SOUTH AMERICA; TIME FACTOR; TREATMENT OUTCOME;

AGED; ASIA; AUSTRALIA; BIOMARKERS; BIPHASIC INSULINS; BLOOD GLUCOSE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN, ISOPHANE; MALE; METFORMIN; MIDDLE AGED; SITAGLIPTIN PHOSPHATE; SOUTH AMERICA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84934945520     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2014.11.001     Document Type: Article

References (15)

1. American Diabetes Association Standards of Medical Care in, Diabetes - 2014 Diabetes Care 37 2014 S14 S80
2. A.J. Garber, M.J. Abrahamson, J.I. Barzilay, and et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement Endocr. Pract. 19 2013 1 48
3. B. Ahrén Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events Best Pract. Res. Clin. Endocrinol. Metab. 23 2009 487 498
4. C.F. Deacon Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review Diabetes Obes. Metab. 13 2011 7 18
5. P. Aschner, J. Chan, D.R. Owens, and et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre randomised open-label trial Lancet 379 2012 2262 2269
6. P. Hollander, K. Raslova, T.V. Skjøth, and et al. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial Diabetes Obes. Metab. 13 2011 268 275
7. J. Seufert, K. Pegelow, and P. Bramlage Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study Vasc. Health Risk Manag. 9 2013 711 717
8. P. Levy Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes Med. Gen. Med. 9 2007 12
9. M. Kvapil, A. Swatko, C. Hilberg, and M. Shestakova Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes Diabetes Obes. Metab. 8 2006 39 48
10. I. Raz, U. Mouritzen, J. Vaz, and et al. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that are poorly controlled with glibenclamide monotherapy Clin. Ther. 25 2003 3109 3123
11. I. Raz, S. Stranks, R. Filipczak, and et al. Efficacy and safety of bisphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomised, open-label study Clin. Ther. 27 2005 1432 1443
12. Novo Nordisk Insulin NovoMix 30 SmPC 2014 Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000308/WC500029441.pdf (accessed June 2014)
13. M. Brod, T. Christensen, M. Hammer, and et al. Examining the ability to detect change using the TRIM-Diabetes and TRIM-Diabetes Device measures Qual. Life Res. 20 2011 1513 1518
14. I.M. Stratton, A.I. Adler, A.W. Neil, and et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412
15. A.J. Garber, J. Wahlen, T. Wahl, and et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study) Diabetes Obes. Metab. 8 2006 58 66